GRIP Influenza and SARS-CoV-2 POC Assays Using Fresh Patient Nasal Swabs


About this study

The objectives of this study are to compare the performance of a novel, graphene-based, point-of-care device to routine laboratory-based molecular tests for detection of respiratory viruses, such as COVID-19 and influenza, and to determine if the novel, graphene-based assay provides enhanced sensitivity for detecting respiratory viruses compared to point-of-care antigen tests.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients ≥ 18 years of age being tested for COVID 19 or Influenza.

Exclusion Criteria:

  • Patients < 18 years of age.

Eligibility last updated 10/27/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Binnicker, Ph.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer